CN101732513B - Shoumingshan capsules for treating hyperlipidemia and method for preparing same - Google Patents
Shoumingshan capsules for treating hyperlipidemia and method for preparing same Download PDFInfo
- Publication number
- CN101732513B CN101732513B CN2010101212146A CN201010121214A CN101732513B CN 101732513 B CN101732513 B CN 101732513B CN 2010101212146 A CN2010101212146 A CN 2010101212146A CN 201010121214 A CN201010121214 A CN 201010121214A CN 101732513 B CN101732513 B CN 101732513B
- Authority
- CN
- China
- Prior art keywords
- capsules
- shoumingshan
- vinegar
- oletum trogopterori
- percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 29
- 208000031226 Hyperlipidaemia Diseases 0.000 title abstract description 9
- 238000000034 method Methods 0.000 title description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 35
- 235000021419 vinegar Nutrition 0.000 claims abstract description 28
- 239000000052 vinegar Substances 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 239000000706 filtrate Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000005303 weighing Methods 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 16
- 210000000582 semen Anatomy 0.000 claims description 14
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 11
- 235000007164 Oryza sativa Nutrition 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 235000009566 rice Nutrition 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 240000007594 Oryza sativa Species 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 17
- 239000008280 blood Substances 0.000 abstract description 17
- 239000000203 mixture Substances 0.000 abstract description 8
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 3
- 208000002173 dizziness Diseases 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 abstract description 3
- 208000026435 phlegm Diseases 0.000 abstract description 3
- 206010008479 Chest Pain Diseases 0.000 abstract description 2
- 206010014080 Ecchymosis Diseases 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 210000003127 knee Anatomy 0.000 abstract description 2
- 210000003800 pharynx Anatomy 0.000 abstract description 2
- 241000301400 Trogopterus Species 0.000 abstract 3
- 241000233948 Typha Species 0.000 abstract 3
- 210000003608 fece Anatomy 0.000 abstract 3
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 2
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 2
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 2
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 2
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 2
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 2
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 2
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 2
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 2
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 2
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 2
- 240000001341 Reynoutria japonica Species 0.000 abstract 2
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 2
- 206010047513 Vision blurred Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 230000003340 mental effect Effects 0.000 abstract 1
- 208000016254 weariness Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 19
- 235000012000 cholesterol Nutrition 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 7
- 241000209094 Oryza Species 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- -1 polyene unsaturated fatty acid Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 241000209514 Alismataceae Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241001518821 Typha orientalis Species 0.000 description 1
- 241000233945 Typhaceae Species 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to Shoumingshan capsules for treating hyperlipidemia. The capsules are prepared from the following raw materials in percentage by weight: 15 to 25 percent of tuber fleeceflower root, 15 to 25 percent of hawthorn fruit, 15 to 25 percent of cassia seed, 5 to 15 percent of vinegar fried trogopterus dung, fried cattail pollen, and 15 to 30 percent of oriental waterplantain rhizome. The preparation method comprises the following steps of: preparing the vinegar fried trogopterus dung and the fried cattail pollen; and weighing the tuber fleeceflower root, the hawthorn fruit, the cassia seed, the vinegar fried trogopterus dung, the fried cattail pollen and the oriental waterplantain rhizome in a weight ratio and mixing, adding water into the mixture, decocting the mixture for three times, filtering and mixing the filtrate, condensing the filtrate, adding ethanol, standing the mixture, and then condensing and drying the mixture to obtain the Shoumingshan capsules. The Shoumingshan capsules have the functions of nourishing the liver and kidney, activating blood circulation to dissipate blood stasis and eliminating phlegm and reducing turbidity, and can be used for treating deficiency of liver-yin and kidney-yin and phlegm-stasis blockade type essential hyperlipidemia, such as dizziness, blurred vision, chest pain, mental weariness, soreness of the waist and knees, dry pharynx and thirsty mouth, tongue ecchymosis and slimy tongue fur.
Description
Technical field
The present invention relates to a kind of Shoumingshan capsules that is used for the treatment of hyperlipemia, also relate to the preparation method of this medicine.
Background technology
Hyperlipemia is commonly called as hyperlipidemia, is meant the class disease that cholesterol in the blood plasma that is caused by a variety of causes or triglyceride levels raise or the both raises.Hyperlipidemia is the arch-criminal who causes cardiovascular and cerebrovascular disease, and sickness rate is more than 7%, and China has 9,000 ten thousand people to suffer from hyperlipidemia approximately.Cholesterol, triglyceride levels raise in the hyperlipidemia blood plasma, often show as a certain class and the rising of a few class lipoprotein levels in the blood plasma, hyperlipidemia is with simple hypercholesterolemia or simple hypertriglyceridemia or both double metabolism disorder of blood lipid diseases of seeing.
Blood lipid-lowering medicine commonly used at present has following a few class:
1. the special class of shellfish: as fenofibrate, bezafibrate etc., this type of medicine effect for reducing blood fat is strong, and is rapid-action, and the effect of triglyceride reducing is stronger than the effect of cholesterol reducing, but easily causes digestive tract reaction, anaphylaxis.
2. Statins: this type of medicine has lovastatin, simvastatin etc., and this type of medicine is based on cholesterol reducing, and effect for reducing fat is strong, and is rapid-action, but easily causes gastrointestinal symptom and erythra.
3. nicotinic acid class: this type of drug dose is excessive untoward reaction such as liver poisoning, hyperglycemia.
4. polyene unsaturated fatty acid class: this class medicine has blood fat reducing and reduces the effect of blood viscosity, but effect is relatively gentleer, and easily is oxidized to atherogenic material.
Summary of the invention
Purpose of the present invention just provides a kind of Shoumingshan capsules of treatment hyperlipemia of determined curative effect.
Another object of the present invention provides the preparation method of Shoumingshan capsules.
Each component pharmacological action that the present invention is selected:
Radix Polygoni Multiflori is the root piece of Polygonaceae herbaceos perennial Radix Polygoni Multiflori, the abnormal smells from the patient bitter cold, contain anthraquinones such as chrysophanic acid, emodin, chrysophanol, aloe-emodin, can promote intestinal peristalsis promoting, reduce cholesterol absorption, increased excretions of cholesterol is drained, thereby plays blood fat reducing, antiatherogenic effect.
Fructus Crataegi is the fruit of Rosaceae machaka or dungarunga plant Crataegi cuneatae, the sweet tepor of nature and flavor acid, contain class materials such as Crataegolic acid, tartaric acid, citric acid, contain a large amount of vitamin Cs and trace element, have the effect of blood circulation promoting and blood stasis dispelling, promoting digestion and invigorating the stomach, hypertension and hyperlipemia and expansion coronary vasodilator, blood vessel dilating is arranged, bring high blood pressure down, cholesterol reducing increases effects such as gastric juice digestive enzyme.
Semen Cassiae is the mature seed of blunt leaf Semen Cassiae of pulse family annual plant or Semen Cassiae, be the Chinese medicine that a kind of sweet-bitter flavor is slightly cold, mainly contain phytosterol and anthraquinones, have and suppress the effect that serum cholesterol raises and atheromatous plaque forms, lipid-lowering effect is remarkable.
The Oletum Trogopterori bitter in the mouth, sweet, warm in nature, promoting blood circulation and stopping pain, removing stasis to stop bleeding, the removing food stagnancy detoxifcation, Oletum Trogopterori is joined Pollen Typhae, promoting blood circulation, promoting blood circulation to remove blood stasis, reducing swelling and alleviating pain strength strengthens, with controlling qi depression to blood stasis, all diseases of trusted subordinate's pain (comprising the angina pectoris that coronary heart disease causes).
Pollen Typhae is the pollen of Typhaceae aquatic herbaceous plant raupo Pollen Typhae, and nature and flavor are sweet flat, contain plant sterols such as sitosterol, stigmasterol, campesterol, can suppress the exogenous cholesterol of intestinal absorption, thereby play the effect of blood fat reducing.But have only Pollen Tyjphae that effect is arranged, Pollen Typhae oil and residue do not have this drug effect.
Rhizoma Alismatis is the tuber of the perennial limnocryptophyte Rhizoma Alismatis of Alismataceae, and slightly sweet flavor is cold in nature, contains triterpenoid compound, can influence steatolysis, the raw material of synthetic cholesterol is reduced, thereby have blood fat reducing, prevents and treats the effect of atherosclerosis and fatty liver.
Each component of Shoumingshan capsules of the present invention all has certain inhibition cholesterol, the effect of blood fat reducing, thus the collaborative pharmacological action that the present invention is based on its various components can more effective treatment hyperlipemia.
Shoumingshan capsules of the present invention is made by the raw material of following weight ratio:
Radix Polygoni Multiflori 15%-25% Fructus Crataegi 15%-25% Semen Cassiae 15%-25%
Processed with vinegar Oletum Trogopterori 5%-15% Pollen Tyjphae (parched) 5%-15% Rhizoma Alismatis 15%-30%
Shoumingshan capsules of the present invention, most preferred raw material weight is composed as follows:
Radix Polygoni Multiflori 19% Fructus Crataegi 19% Semen Cassiae 19%
Processed with vinegar Oletum Trogopterori 9.5% Pollen Tyjphae (parched) 9.5% Rhizoma Alismatis 24%
The preparation method of Shoumingshan capsules of the present invention comprises the steps:
(1) clean Oletum Trogopterori is put in the pot, after slow fire is made popular, evenly sprayed rice vinegar, it is little when glossy to the surface to stir-fry again, and taking-up is dried, the processed with vinegar Oletum Trogopterori; Clean Pollen Typhae is put pot interior slow fire fry to yellowish-brown, taking-up cools and promptly gets Pollen Tyjphae (parched);
(2) take by weighing Six-element such as Radix Polygoni Multiflori, Fructus Crataegi, Semen Cassiae, processed with vinegar Oletum Trogopterori, Pollen Tyjphae (parched), Rhizoma Alismatis and this Six-element medicine decocted with water three times by weight, 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, filter decocting liquid, merging filtrate;
(3) concentrate above-mentioned filtrate to extractum (d=1.10～1.12,70 ℃), adding ethanol, to make pure weight fraction be 50-70%, leaves standstill 24h;
(4) reclaim ethanol and be concentrated into extractum (d=1.25～1.30,90 ℃), be drying to obtain the active component of medicine of the present invention;
(5) active component with medicine of the present invention mixes with medical starch, granulate, and granulate, encapsulated, promptly get Shoumingshan capsules agent of the present invention.
In addition, for ease of taking, the active component of Shoumingshan capsules agent medicine of the present invention can also be prepared into various pharmaceutically acceptable dosage forms with pharmaceutically acceptable carrier, comprises decoction, powder, tablet, granule.
Shoumingshan capsules function tonification Liver and kidney of the present invention, blood circulation promoting and blood stasis dispelling, the turbid descending that eliminates the phlegm is used for the hepatic and renal YIN deficiency, expectorant stasis of blood accumulation type Primary hyperlipemia, disease is seen dizziness, and is dizzy, chest pain, Mental fatigue, soreness of the waist and knees, parched throat xerostomia, tongue with ecchymosis, greasy fur.
The specific embodiment
One. the test example
1. clinical research
Research material: the treatment group is taken medicine Shoumingshan capsules of the present invention (every contains medicated powder 0.22 gram, is equivalent to 3.6 gram crude drugs); Matched group is taken MAIAN KELI (every bag 20 gram).
Research method: observe 437 routine hyperlipidemia patients altogether, be divided into 2 groups at random, wherein 326 examples are organized in treatment, matched group 111 examples.Male's 231 examples, women's 206 examples are the married.Minimum 1 example of treatment group age 5 years old, maximum age 1 example 79 years old, 55.88 ± 7.16 years old mean age; Minimum 1 example of matched group age 2 years old, maximum age 1 example 79 years old, 56.47 ± 11.26 years old mean age.Treatment group average course of disease is 2.94 ± 1.25 years, and matched group is 3.01 ± 0.92 years, and two groups of contrast differences are significantly (P＞0.05) not.
Method of administration is taken Shoumingshan capsules for the treatment group, and each 4, every day three times; Matched group is taken MAIAN KELI, and each one bag (every bag 20 gram) is a course of treatment every day 3 times all around, serve on two courses of treatment.
Warp is to the hyperlipemia clinical trial, and observed result is as follows:
Table 1 Shoumingshan capsules is to the influence of blood fat (x ± s)
Self contrasts: *: p＜0.05,
*P＜0.01,
* *Contrast between P＜0.01 group:
▲ ▲P＜0.001
Table 2 liang group patient symptom curative effect (example/%)
| Group | n | Produce effects | Effectively | Invalid | Total effective rate |
| The treatment group | 326 | 36.80 | 48.78 | 14.42 | 85.58 |
| Matched group | 111 | 22.52 | 40.54 | 36.94 | 63.06 |
Compare P＜0.01 with matched group
Table 3 Shoumingshan capsules accent fat curative effect situation (example/%)
| Group | n | Produce effects | Effectively | Invalid | Worsen | Total effective rate |
| The treatment group | TC?n＝150 | 51(34.0) | 68(45.3) | 28(18.7) | 3(2.0) | 79.3 |
| Matched group | TC?n＝44 | 15(34.1) | 10(22.7) | 14(31.8) | 5(11.4) | 56.8 |
| The treatment group | TG?n＝240 | 82(34.2) | 95(39.6) | 45(18.7) | 18(7.5) | 73.8 |
| Matched group | TG?n＝78 | 21(26.9) | 31(39.8) | 16(20.5) | 10(12.8) | 66.7 |
| The treatment group | HDL-C?n＝194 | 91(46.9) | 65(33.5) | 31(15.9) | 7(3.7) | 80.4 |
| Matched group | HDL-C?n71＝ | 23(32.4) | 18(25.4) | 20(28.1) | 10(14.1) | 57.8 |
| The treatment group | AI?n＝269 | 169(62.8) | 57(21.2) | 32(11.9) | 11(4.1) | 84.0 |
| Matched group | AI?n＝90 | 30(33.3) | 28(31.1) | 20(22.2) | 12(13.4) | 64.4 |
Contrast between group: through X
2Check, blood fat curative effect TC, HDL, the equal highly significant P of AI differences＜0.01
Observed result shows: symptom curative effect treatment group total effective rate is 85.58%, the matched group total effective rate is 63.06%, two groups of contrasts are learned by statistics and are handled, difference highly significant (P＜0.01), reducing TG (triglyceride) total effective rate treatment group is 73.8%, matched group is 66.7%, two groups of contrast differences are significantly (P＞0.05%) not, (high density lipoprotein total effective rate treatment group is 80.4% to rising HDL-C, matched group is 57.8%, two groups of contrast difference's highly significants (P＜0.01), reducing AI (atherogenic index) total effective rate treatment group is that 84% matched group is 64.4%, two group of contrast difference's highly significant (P＜0.01).
2. pharmacological toxicology research
Acute toxicity test: select 20 of the white mice of healthy purebred LACA20g body weight, twice on the half and half, one gastric infusion of male and female, 330 times of being equivalent to be grown up of dosage, observed seven days, none animal dead and abnormal phenomena take place, and illustrate that heavy dose of Shoumingshan capsules does not have acute toxic reaction.
Long term toxicity test: through purebred SD rat oral gavage, every day was by 80 times, 40 times, 10 times administrations of adult's dose, totally 90 days.The result shows that Shoumingshan capsules toxicity is less, and by 3.34 grams of taking medicine every day, 5 weeks of the course of treatment are safe.
Two. preparation example
Preparation example 1
Clean Oletum Trogopterori is put in the pot, after slow fire is made popular, evenly sprayed rice vinegar, it is little when glossy to the surface to stir-fry again, and taking-up is dried, the processed with vinegar Oletum Trogopterori is standby; Clean Pollen Typhae is put pot interior slow fire fry, take out and to cool that promptly to get Pollen Tyjphae (parched) standby to yellowish-brown; Take by weighing following raw materials in weight: Radix Polygoni Multiflori 1200 grams, Fructus Crataegi 1200 grams, Semen Cassiae 1200 grams, processed with vinegar Oletum Trogopterori 600 grams, Pollen Tyjphae (parched) 600 grams, Rhizoma Alismatis 1500 grams, above Six-element, decoct with water three times, 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, decocting liquid filtered, filtrate merges, being concentrated into the extractum relative density is 1.10 (70 ℃), adds ethanol and makes and contain alcohol amount and reach 60%, leaves standstill 24h, reclaim ethanol and be concentrated into extractum relative density 1.25 (90 ℃), mix with medical starch dry back, granulates granulate, encapsulated, promptly get Shoumingshan capsules of the present invention.
Preparation example 2
Clean Oletum Trogopterori is put in the pot, after slow fire is made popular, evenly sprayed rice vinegar, it is little when glossy to the surface to stir-fry again, and taking-up is dried, the processed with vinegar Oletum Trogopterori is standby; Clean Pollen Typhae is put pot interior slow fire fry, take out and to cool that promptly to get Pollen Tyjphae (parched) standby to yellowish-brown; Take by weighing following raw materials in weight: Radix Polygoni Multiflori 2400 grams, Fructus Crataegi 2400 grams, Semen Cassiae 2400 grams, processed with vinegar Oletum Trogopterori 600 grams, Pollen Tyjphae (parched) 600 grams, Rhizoma Alismatis 1600 grams, above Six-element, decoct with water three times, 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, decocting liquid filtered, filtrate merges, being concentrated into the extractum relative density is 1.12 (70 ℃), adds ethanol and makes and contain alcohol amount and reach 55%, leaves standstill 24h, reclaim ethanol and be concentrated into extractum relative density 1.25 (90 ℃), mix with medical starch dry back, granulates granulate, encapsulated, promptly get Shoumingshan capsules of the present invention.
Preparation example 3
Clean Oletum Trogopterori is put in the pot, after slow fire is made popular, evenly sprayed rice vinegar, it is little when glossy to the surface to stir-fry again, and taking-up is dried, the processed with vinegar Oletum Trogopterori is standby; Clean Pollen Typhae is put pot interior slow fire fry, take out and to cool that promptly to get Pollen Tyjphae (parched) standby to yellowish-brown; Take by weighing following raw materials in weight: Radix Polygoni Multiflori 1600 grams, Fructus Crataegi 1600 grams, Semen Cassiae 1600 grams, processed with vinegar Oletum Trogopterori 1200 grams, Pollen Tyjphae (parched) 1200 grams, Rhizoma Alismatis 2800 grams, above Six-element, decoct with water three times, 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, decocting liquid filtered, filtrate merges, being concentrated into the extractum relative density is 1.10 (70 ℃), adds ethanol and makes and contain alcohol amount and reach 70%, leaves standstill 24h, reclaim ethanol and be concentrated into extractum relative density 1.30 (90 ℃), mix with medical starch dry back, granulates granulate, encapsulated, promptly get Shoumingshan capsules of the present invention.
Preparation example 4 (preparation of medicinal tablet of the present invention)
Clean Oletum Trogopterori is put in the pot, after slow fire is made popular, evenly sprayed rice vinegar, it is little when glossy to the surface to stir-fry again, and taking-up is dried, the processed with vinegar Oletum Trogopterori is standby; Clean Pollen Typhae is put pot interior slow fire fry, take out and to cool that promptly to get Pollen Tyjphae (parched) standby to yellowish-brown; Take by weighing following raw materials in weight: Radix Polygoni Multiflori 1000 grams, Fructus Crataegi 1000 grams, Semen Cassiae 1000 grams, processed with vinegar Oletum Trogopterori 500 grams, Pollen Tyjphae (parched) 500 grams, Rhizoma Alismatis 1250 grams, above Six-element decocts with water three times, 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, decocting liquid filters, filtrate merges, and being concentrated into the extractum relative density is 1.12 (70 ℃), adds ethanol and makes and contain the alcohol amount and reach 50%, leave standstill 24h, reclaim ethanol and be concentrated into extractum relative density 1.25 (90 ℃), drying is ground into fine powder, with the right amount of auxiliary materials mixing, granulate, drying adds an amount of magnesium stearate, mix, tabletting, coating promptly gets the medicinal tablet of treatment hyperlipemia of the present invention.
Preparation example 5 (preparation of medicinal granule of the present invention)
Clean Oletum Trogopterori is put in the pot, after slow fire is made popular, evenly sprayed rice vinegar, it is little when glossy to the surface to stir-fry again, and taking-up is dried, the processed with vinegar Oletum Trogopterori is standby; Clean Pollen Typhae is put pot interior slow fire fry, take out and to cool that promptly to get Pollen Tyjphae (parched) standby to yellowish-brown; Take by weighing following raw materials in weight: Radix Polygoni Multiflori 1800 grams, Fructus Crataegi 1800 grams, Semen Cassiae 1800 grams, processed with vinegar Oletum Trogopterori 900 grams, Pollen Tyjphae (parched) 900 grams, Rhizoma Alismatis 2250 grams, above Six-element decocts with water three times, 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, decocting liquid filtered, and filtrate merges, being concentrated into the extractum relative density is 1.10 (70 ℃), add ethanol and make and contain alcohol amount and reach 70%, leave standstill 24h, reclaim ethanol and also be concentrated into extractum relative density 1.30 (90 ℃), dry, be ground into fine powder,, granulate with the appropriate amount of auxiliary materials mixing, dry, granulate is packed, and promptly gets the medicinal granule of treatment hyperlipemia of the present invention.
Claims (3)
1. Shoumingshan capsules that is used for the treatment of hyperlipemia is characterized in that being made by the raw material of following weight ratio:
Radix Polygoni Multiflori 15%-25% Fructus Crataegi 15%-25% Semen Cassiae 15%-25%
Processed with vinegar Oletum Trogopterori 5%-15% Pollen Tyjphae (parched) 5%-15% Rhizoma Alismatis 15%-30%.
2. Shoumingshan capsules according to claim 1 is characterized in that the weight of each raw material is composed as follows:
Radix Polygoni Multiflori 19% Fructus Crataegi 19% Semen Cassiae 19%
Processed with vinegar Oletum Trogopterori 9.5% Pollen Tyjphae (parched) 9.5% Rhizoma Alismatis 24%.
3. the preparation method of claim 1 or 2 described Shoumingshan capsules is characterized in that comprising the steps:
(1) clean Oletum Trogopterori is put in the pot, after slow fire is made popular, evenly sprayed rice vinegar, it is little when glossy to the surface to stir-fry again, and taking-up is dried, the processed with vinegar Oletum Trogopterori; Clean Pollen Typhae is put pot interior slow fire fry to yellowish-brown, taking-up cools and promptly gets Pollen Tyjphae (parched);
(2) take by weighing Six-element such as Radix Polygoni Multiflori, Fructus Crataegi, Semen Cassiae, processed with vinegar Oletum Trogopterori, Pollen Tyjphae (parched), Rhizoma Alismatis and this Six-element medicine decocted with water three times by weight, 2 hours for the first time, 1.5 hours for the second time, 1 hour for the third time, filter decocting liquid, merging filtrate;
Relative density is 1.10～1.12 extractum when (3) concentrating above-mentioned filtrate to 70 ℃, and adding ethanol, to make pure weight fraction be 50-70%, leaves standstill 24h;
(4) reclaim ethanol and when being concentrated into 90 ℃ relative density be 1.25～1.30 extractum, be drying to obtain the active component of medicine;
(5) active component with medicine mixes with medical starch, granulate, and granulate, encapsulated, promptly get the Shoumingshan capsules agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101212146A CN101732513B (en) | 2009-09-16 | 2010-02-07 | Shoumingshan capsules for treating hyperlipidemia and method for preparing same |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910018747.9 | 2009-09-16 | ||
| CN200910018747A CN101653522A (en) | 2009-09-16 | 2009-09-16 | Medicine for curing hyperlipemia and preparation method thereof |
| CN2010101212146A CN101732513B (en) | 2009-09-16 | 2010-02-07 | Shoumingshan capsules for treating hyperlipidemia and method for preparing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101732513A CN101732513A (en) | 2010-06-16 |
| CN101732513B true CN101732513B (en) | 2011-04-06 |
Family
ID=42456881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101212146A Active CN101732513B (en) | 2009-09-16 | 2010-02-07 | Shoumingshan capsules for treating hyperlipidemia and method for preparing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101732513B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104055962A (en) * | 2013-03-22 | 2014-09-24 | 王文才 | Dietotherapy composition for reducing blood lipid |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101069737A (en) * | 2007-06-08 | 2007-11-14 | 郭永德 | Chinese herbal medicine oral liquor for reducing humanbody cholesterin and regulating blood-fat and clearing intestines and relaxing the bowels |
| CN101337057A (en) * | 2008-08-12 | 2009-01-07 | 浙江省医学科学院 | Zhiqing granule and preparation method thereof |
-
2010
- 2010-02-07 CN CN2010101212146A patent/CN101732513B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101069737A (en) * | 2007-06-08 | 2007-11-14 | 郭永德 | Chinese herbal medicine oral liquor for reducing humanbody cholesterin and regulating blood-fat and clearing intestines and relaxing the bowels |
| CN101337057A (en) * | 2008-08-12 | 2009-01-07 | 浙江省医学科学院 | Zhiqing granule and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101732513A (en) | 2010-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101461896B (en) | Chinese medicinal composition assistant for reducing blood fat and preparation method thereof | |
| CN102846852A (en) | Composite for lowering blood fat and regulating immunity | |
| CN101496872A (en) | Chinese medicinal composition for reducing blood fat and preparation method thereof | |
| CN104757540A (en) | Health-care product assisted to reduce blood glucose and preparation method thereof | |
| CN105031517A (en) | Dendrobium officinale healthcare tea capable of reducing blood fat, blood sugar, and blood pressure and preparation method thereof | |
| CN104208581A (en) | Schisandra chinensis health care oral liquid capable of preventing alcoholic liver and preparation method thereof | |
| CN102366605A (en) | Traditional Chinese medicine preparation for treating hypertension and hyperlipidemia, and its preparation method | |
| CN101243882B (en) | Health food with function of reducing blood fat and its preparation | |
| CN101711798A (en) | Preparation used for lowering blood fat and lowering blood sugar | |
| CN105412277A (en) | Traditional Chinese medicinal composition of lipid-lowering tea and application of traditional Chinese medicinal composition | |
| CN101524441A (en) | Chinese medicinal composition for lipid-lowering and weight-losing and preparation method thereof | |
| CN102423382A (en) | Chinese medicine composition for treating dyslipidemia and application thereof | |
| CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
| CN102178798A (en) | Preparation for reducing blood fat, preventing and treating cardiovascular and cerebrovascular diseases | |
| CN101732513B (en) | Shoumingshan capsules for treating hyperlipidemia and method for preparing same | |
| WO2023100764A1 (en) | Composition for preventing, improving or alleviating symptoms relating to qi deficiency and/or blood deficiency | |
| CN105685994A (en) | Healthcare food capable of assisting in blood lipid reduction and preparation method and application of healthcare food capable of assisting in blood lipid reduction | |
| CN104286864A (en) | Flatstem milkvetch seed oral liquid for improving immunity and preparation method thereof | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| CN101112457B (en) | Health-care oral liquid for slimming, reducing fat, taking good care of skin, expelling toxin and strengthening stomach | |
| CN1115159C (en) | Red sage containing medicine composition and its preparation and use | |
| CN101653522A (en) | Medicine for curing hyperlipemia and preparation method thereof | |
| CN101480434A (en) | Compound recipe for reducing blood fat as well as preparation method and application | |
| CN104800600A (en) | Medicine for treating hypertension | |
| CN109925451A (en) | A kind of lower blood-fat and reduce weight tea-drinking |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: WANG HAOHUA Free format text: FORMER OWNER: MA ZHAOCHEN Effective date: 20130204 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 255190 ZIBO, SHANDONG PROVINCE TO: 250100 JINAN, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130204 Address after: 250100 No. 131 Industrial Road, Licheng District, Shandong, Ji'nan Patentee after: Wang Haohua Address before: 255190 Shandong city in Zibo province Shuangfeng science and Technology Industrial Park Patentee before: Ma Zhaochen |
|
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG HUAYANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG HAOHUA Effective date: 20130620 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250100 JINAN, SHANDONG PROVINCE TO: 255190 ZIBO, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130620 Address after: 255190 Shandong city in Zibo province Shuangfeng science and Technology Industrial Park Patentee after: Shandong Huayang Pharmaceutical Co., Ltd. Address before: 250100 No. 131 Industrial Road, Licheng District, Shandong, Ji'nan Patentee before: Wang Haohua |